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In the resting cell, chromatin is tightly com-
pacted to prevent transcription factor acces-
sibility. During activation of the cell this 
compact inaccessible chromatin is made avail-
able to DNA-binding proteins, thus allowing 
the induction of gene transcription (1, 2). 
There is compelling evidence that increased 
gene transcription is associated with an increase 
in histone acetylation induced by histone ace-
tyltransferase, whereas hypo-acetylation is cor-
related with reduced transcription or gene 
silencing (2, 3), which is controlled by histone 
deacetylases (HDACs).
At least 18 HDACs are now recognized in 
mammalian cells (4, 5) and are grouped into 4 
classes based on similarity of genes in yeast. In 
previous studies, we have found that total nu-
clear HDAC activity and HDAC2 expression 
are decreased in lung macrophages and periph-
eral lung tissue obtained from chronic obstruc-
tive pulmonary disease (COPD) (6, 7) and that 
the reduction correlates with disease severity.
CORRESPONDENCE
Kazuhiro Ito:
k.ito @ imperial.ac.uk
CORRESPONDENCE
Kazuhiro Ito:
k.ito @ imperial.ac.uk
Glucocorticoids are the most eff  ective ther-
apy for the treatment of many chronic infl  am-
matory diseases such as asthma and infl  ammatory 
bowel disease (8). They act by binding to cyto-
solic glucocorticoid receptors (GRs), which 
upon binding become activated and rapidly 
translocate to the nucleus. Within the nucleus, 
GR either induces transcription of genes, such 
as secretary leukocyte proteinase inhibitor 
(SLPI) (8) and mitogen-activated kinase phos-
phatase–1 (9), or inhibits expression of genes 
such as IL-6 (10) by binding to specifi  c DNA 
elements (glucocorticoid response elements 
[GREs]) at the promoter/enhancer of respon-
sive genes. At lower concentrations, glucocor-
ticoids reduce infl  ammatory gene transcription 
induced by NF-κB or AP-1 via association be-
tween these factors and GR (11). In addition, 
Ogawa et al. also show that the GR represses a 
large set of functionally related infl  ammatory 
response genes by disrupting p65–interferon 
regulatory factor complexes (12). Thus, binding 
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Glucocorticoids are the most effective antiinfl  ammatory agents for the treatment of chronic 
infl  ammatory diseases even though some diseases, such as chronic obstructive pulmonary 
disease (COPD), are relatively glucocorticoid insensitive. However, the molecular mechanism 
of this glucocorticoid insensitivity remains uncertain. We show that a defect of glucocorti-
coid receptor (GR) deacetylation caused by impaired histone deacetylase (HDAC) 2 induces 
glucocorticoid insensitivity toward nuclear factor (NF)-𝗋B–mediated gene expression. Speci-
fi  c knockdown of HDAC2 by RNA interference resulted in reduced sensitivity to dexame-
thasone suppression of interleukin 1𝗃–induced granulocyte/macrophage colony-stimulating 
factor production. Loss of HDAC2 did not reduce GR nuclear translocation, GR binding to 
glucocorticoid response element (GRE) on DNA, or GR-induced DNA or gene induction but 
inhibited the association between GR and NF-𝗋B. GR becomes acetylated after ligand bind-
ing, and HDAC2-mediated GR deacetylation enables GR binding to the NF-𝗋B complex. Site-
directed mutagenesis of K494 and K495 reduced GR acetylation, and the ability to repress 
NF-𝗋B–dependent gene expression becomes insensitive to histone deacetylase inhibition. In 
conclusion, we show that overexpression of HDAC2 in glucocorticoid-insensitive alveolar 
macrophages from patients with COPD is able to restore glucocorticoid sensitivity. Thus, re-
duction of HDAC2 plays a critical role in glucocorticoid insensitivity in repressing NF-𝗋B–
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Figure 1.  HDAC2 KD-induced glucocorticoid insensitivity in A549 
cells. (A) Dot blot analysis of nuclear extracts from A549 cells 48 h after 
transfection with siRNA against HDAC1, -2, -3, and -8; Sc; or vehicle only 
(NT). (B) IL-1β–stimulated (1 ng/ml for 24 h) GM-CSF production. Values 
represent means ± SEM. * and **, P < 0.05 and P < 0.01, respectively, 
versus IL-1β control; #, P < 0.05 versus basal control. n = 4 8 experi-
ments. (C) Concentration response curve of Dex suppression of IL-1β–
induced GM-CSF production, and (D) summarized EC50 values of Dex 
(n = 4 8). Values in C represent means ± SEM. (E) Correlation between 
EC50 and HDAC2 expression in HDAC2 RNAi cells. Different levels of 
HDAC2 expression were induced using individual siRNA or combinations 
of up to four duplexes against HDAC2. HDAC2 expression evaluated by 
Western blotting was shown as the percentage of that in nontreated cells. 
Dashed and continuous lines represent 95% confi  dence interval.
Figure 2.  HDAC2 KD does not inhibit GR-mediated gene activa-
tion. (A) GR nuclear translocation in Sc and HDAC2 siRNAs (H2) trans-
fected cells stimulated with 10−8 M Dex for 1 h. β-Actin and histone H1 
were used as loading controls. GR-GRE binding (B), GRE-luciferase activ-
ity (C), and SLPI gene induction (D). * and **, P < 0.05 and P < 0.01, re-
spectively (n = 3 experiments). NT, nontreated. (E) GR-GRE binding 1 h 
(closed circle) and 8 h (open circle) after Dex stimulation. Values in B–E 
represent means ± SEM.
of GR to p65–NF-κB is crucial for transrepression by corti-
costeroids. However, it is unclear how the GR dissociates 
its ability to control infl   ammation by suppressing NF-κB 
from its ability to directly transactivate genes via binding 
to GRE.
COPD is a common and debilitating chronic infl  ammatory 
disease characterized by progressive airfl  ow limitation that is 
poorly reversible (13) and glucocorticoid insensitive (14, 15). 
We previously demonstrated that total HDAC activity nega-
tively correlates with the inhibitory eff  ect of dexamethasone JEM VOL. 203, January 23, 2006  9
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(Dex) on TNF-α–induced IL-8 production (16) in alveolar 
macrophages from smokers and nonsmokers. We also re-
ported that theophylline might restore glucocorticoid sen-
sitivity via enhancement of HDAC activity in COPD 
macrophages (7). However, it has not been elucidated which 
HDAC regulates glucocorticoid sensitivity nor how it modu-
lates glucocorticoid action.
In this paper, we identifi  ed an HDAC enzyme involved 
in glucocorticoid-dependent repression of NF-κB–induced 
gene expression and provided evidence that HDAC2 over-
expression was able to restore glucocorticoid sensitivity in 
glucocorticoid insensitive diseases such as COPD.
RESULTS AND DISCUSSION
Loss of HDAC2 induced glucocorticoid insensitivity
We initially assessed whether loss of specifi  c HDAC enzymes 
induced glucocorticoid insensitivity on IL-1β–induced GM-
CSF production, which is NF-κB mediated, as previously 
  reported (17, 18) and from our data showing concentration-
dependent inhibition by IκB kinase 2 inhibitor (AS602868; 
IC50 = 3.6 × 10−6 M). Class I HDAC enzymes (HDAC1, -2, 
-3, and -8) (4) were selectively knocked down by RNA in-
terference in A549 cells (Fig. 1 A). [ID]FIG1[/ID] When GM-CSF produc-
tion was normalized to viable cell numbers, HDAC2 (1,057.1 
± 209.3 ng/106 cells), HDAC3 (910.5 ± 230.5 ng/106 cells), 
and HDAC8 (919.5 ± 64.8 ng/106 cells) knockdown (KD), 
but not HDAC1 KD, signifi  cantly enhanced IL-1β–induced 
GM-CSF production (vs. 335.0 ± 55.5 ng/106 cells in con-
trol; Fig. 1 B). These initial results show that HDAC2, -3, and 
-8 regulate NF-κB–mediated GM-CSF induction. We previ-
ously showed that trichostatin A (TSA), a nonselective HDAC 
inhibitor, enhanced GM-CSF production in A549 cells (19).
Furthermore, HDAC2 KD shifted the concentration-
  dependent inhibition of IL-1β–stimulated GM-CSF release 
by Dex to the right, indicating a reduction in glucocorticoid 
action (Fig. 1, C and D). A similar result was seen after treat-
ment with TSA (19). A similar action was also seen with sup-
pression of IL-1β–induced IL-8 production (Fig. 1 D). In 
contrast, HDAC1, -3, and -8 KD had no eff  ect on Dex action 
on either GM-CSF or IL-8 production (Fig. 1 D). Using in-
dividual short interference RNA (siRNA), or combinations 
of up to four duplexes against HDAC2, we were able to ob-
tain diff  erent levels of HDAC2 reduction in cells (Fig. 1 E). 
This HDAC2 study showed that there was a signifi  cant nega-
tive correlation between HDAC2 expression after RNAi and 
Dex EC50 with respect to IL-1β–induced GM-CSF produc-
tion (r = −0.771; P = 0.0020; Fig. 1 E). This graded reduc-
tion in glucocorticoid responsiveness with reducing HDAC2 
expression suggests that HDAC2 plays an important role in 
the antiinfl  ammatory actions of glucocorticoids. Intriguingly, 
KD of HDAC2 does not aff  ect the maximal response to Dex 
seen at very high concentrations (1 μM; Fig. 1 C) and sug-
gests that, at these supraphysiological concentrations, alterna-
tive mechanisms of action may be occurring (20).
HDAC2 KD did not aff  ect GR expression or nuclear 
translocation (Fig. 2 A). [ID]FIG2[/ID] Loss of HDAC2 did not reduce GR-
GRE binding (Fig. 2 B), GRE-dependent luciferase activity 
(Fig. 2 C), or GRE-mediated SLPI gene expression (Fig. 2 
D). In addition, GR-GRE binding after Dex treatment was 
sustained longer in HDAC2 KD cells than in nontreated cells 
or scrambled oligonucleotide (Sc)–transfected cells (Fig. 2 E).
Loss of HDAC2 inhibited association of GR and NF-𝗋B
In addition, HDAC2 KD did not aff  ect NF-κB expression, 
nuclear translocation (Fig. 3 A), or NF-κB–DNA binding 
(Fig. 3 B).[ID]FIG3[/ID] We confi  rmed previous data showing that Dex 
increased GR and HDAC2 association with the p65–NF-κB 
complex (Fig. 3 A) (19). However, GR was not recruited 
to the p65–NF-κB complex after HDAC2 KD (Fig. 3 A). 
Chromatin immunoprecipitation (ChIP) analysis showed that 
Dex failed to inhibit histone 4 acetylation at the p65–NF-κB 
binding site in the GM-CSF promoter region after HDAC2 
KD (Fig. 3 C). Thus, HDAC2 KD did not reduce the ability 
of GR to induce GR-sensitive gene expression but had a 
Figure 3.  HDAC2 KD causes inhibition of GR–NF-𝗋B association. 
(A) GR and HDAC2 were coimmunoprecipitated with p65–NF-κB in 
  nuclear extracts in the presence or absence of a 30-min treatment of 
IL-1β with or without 20-min pretreatment with 10−9 M Dex. H2, HDAC2. 
(B) NF-κB activation measured by NF-κB binding to oligonucleotides, 
including NF-κB binding site, 30 min after IL-1β treatment (n = 3). 
(C) Histone 4 acetylation of NF-κB binding site at the GM-CSF promoter 
region detected by ChIP assay. Ct (threshold) values of PCR products 
were normalized to those of input samples. *, P < 0.05 versus IL-1β 
 control  (n = 3 experiments). Values in B and C represent means ± SEM.10  HDAC2-DEPENDENT GR DEACETYLATION ON NF-κB SUPPRESSION | Ito et al.
preferential eff  ect on the suppression of NF-κB–mediated in-
fl  ammatory gene expression.
GR is an acetylated protein and deacetylated by HDAC2
Previous studies have shown that both estrogen receptor α 
and androgen receptor are acetylated within their hinge/ 
ligand binding domains and that this can modulate hormone-
induced gene induction (21, 22). This nuclear receptor 
acetylation site is conserved among members of related nu-
clear receptors and, based on these fi  ndings (22), there is a 
potential acetylation site at aa 492–495 (KTKK) within the 
DNA binding domain/hinge region of GR. Indeed, we 
show that GR is acetylated after Dex binding (Fig. 4, A and 
B), and the acetylation levels were decreased when K494 and 
K495 on GR were mutated to alanine (A), asparagine (N), or 
glutamine (Q) (Fig. 4 C). [ID]FIG4[/ID] These mutants did not further in-
duce SLPI expression by Dex even though overexpression of 
native GR enhanced SLPI expression by Dex (Fig. 4 D). 
There was no diff  erence in ability of native or mutant GR 
to bind to p65–NF-κB (Fig. 4 E). However, GR-mediated 
suppression of IL-1β–stimulated GM-CSF release was not 
aff  ected by TSA with the K494 and K495 mutants (Fig. 4 F) 
even though the repression was attenuated by TSA in native 
GR overexpression cells. This suggests that GR acetylation 
negatively regulates Dex-induced repression of NF-κB–de-
pendent gene expression. In addition, we found that p65–
NF-κB–  associated GR was deacetylated (Fig. 4 A). Because 
GR is unable to   associate with the p65–NF-κB complex in 
HDAC2 KD cells, this deacetylation must be important for 
GR-mediated   transrepression (Fig. 4, A and B). Importantly, 
HDAC2 KD does not inhibit GR-GRE binding or SLPI 
transactivation (Fig. 2, B and D), indicating that the acety-
lated GR is still able to activate glucocorticoid-responsive 
genes, which may be involved in some of the deleterious side 
eff  ects that limit the clinical use of these powerful drugs, as 
well as some minor antiinfl  ammatory eff  ects via induction of 
antiinfl  ammatory molecules such as SLPI and MKP-1.
To determine whether acetylated GR was a substrate 
for HDAC2, acetylated GR was immunoprecipitated in 
the presence of Dex and incubated with immunopurifi  ed 
HDAC1, -2, -3, and -8 (adjusted to show the same degree of 
HDAC activity) in a nonisotopic in vitro assay. Acetylated 
GR was clearly a substrate for HDAC2, although it is also 
partially deacetylated by HDAC3 (Fig. 4 G). Thus, acetylated 
GR is a substrate of HDAC2, and deacetylation of GR by 
HDAC2 may be prerequisite for GR association with the 
Figure 4.  GR deacetylation by HDAC2 is a prerequisite for p65–
NF-𝗋B binding. (A) GR was precipitated after vehicle or Dex treatment 
with anti-GR antibody in whole cell extracts and with GRE oligonucleo-
tides or anti-p65–NF-κB antibody in the presence of 10−8 M Dex and 
1 ng/ml IL-1β. Bands were visualized by anti–acetyl-lysine antibody (α-AcK) 
and anti-GR antibody (α-GR). (B) Graphical representation of the results 
shown in A, with the ratio of AcK band to GR band in nontreated (shaded 
bar) and HDAC2 RNAi cells (closed bar). X represents no GR recruitment to 
NF-κB. *, P < 0.05. (C) GR acetylation level of each site-directed mutant 
after treatment with 10−6 M Dex for 1 h. GR were pulled down with 
anti–His-tag antibody. (D) SLPI mRNA level after treatment with 10−6 M 
Dex for 4 h. (E) GR binding to p65 under treatment with 10−8 M Dex for 
1 h. GR is immunoprecipitated with His-tag antibody 1 h after IL-1β 
treatment. (F) Effect of 10−8 M Dex on IL-1β–induced GM-CSF production 
in the presence of 10 nM TSA for 10 min. *, P < 0.05. (G) AcK detection on 
immunoprecipitated GR in the presence of 10−6 M Dex after incubation 
with HDAC1, -2, -3, or -8 for 4 h at 30°C. (bottom) The ratio of AcK 
band to GR band is shown graphically. * and **, P < 0.05 and P < 0.01, 
respectively, versus control (n = 3 experiments). Values in B, D, F, and 
G represent means ± SEM.JEM VOL. 203, January 23, 2006  11
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p65–NF-κB–activated complex and subsequent suppression 
of infl  ammatory gene expression. This mechanism provides 
a molecular explanation for the ability of GR to distinguish 
between recruitment of coactivator and corepressor proteins, 
as previously demonstrated for GRIP (23), and the subse-
quent ability to transactivate or repress gene transcription.
Overexpression of HDAC2 restores glucocorticoid sensitivity 
in alveolar macrophages from glucocorticoid-insensitive 
disease (COPD)
We previously reported that HDAC2 expression and activity 
is decreased in smokers (16) and patients with COPD (6), 
who are known to be insensitive to the antiinfl  ammatory ef-
fects of glucocorticoids (14). In addition, there is a negative 
correlation between the repressive eff  ect of Dex on cytokine 
production and total HDAC activity in alveolar macrophages 
from smokers and nonsmokers (16). To determine whether 
HDAC2 is important for Dex actions in primary cells from 
patients with glucocorticoid-insensitive disease, we obtained 
alveolar macrophages from healthy nonsmokers, healthy 
smokers, and patients with COPD. [ID]FIG5[/ID] There was no substantial 
diff  erence in macrophage GR expression between normal 
and COPD samples (unpublished data). Total HDAC activ-
ity, immunoprecipitated HDAC2 activity (Fig. 5 A), and 
HDAC2 protein expression (Fig. 5 B, NT) were markedly 
decreased in cells from patients with COPD. The acetylation 
level in immunoprecipitated nuclear GR after Dex treatment 
(10−8 M) was increased in alveolar macrophages obtained 
from patients with COPD (Fig. 5 C). In these cells obtained 
from COPD patients, Dex did not inhibit NF-κB–dependent 
(24) LPS-induced GM-CSF production in vitro (Fig. 5 D, 
top). Overexpression of HDAC2 protein by 6.5 ± 1.1-fold 
in primary macrophages from COPD patients (Fig. 5 B) re-
stored Dex effi   cacy toward suppressing LPS-induced GM-
CSF release to levels seen in cells from healthy control subjects 
(Fig. 5 D, middle). In contrast, HDAC2 overexpression by 
3.3 ± 0.86-fold and 5.2 ± 1.1-fold in nonsmokers and smok-
ers, re  spectively, did not further increase Dex effi   cacy toward 
LPS-induced GM-CSF production in cells from nonsmok-
ers/smokers, presumably as these cells are already sensitive to 
Dex actions (Fig. 5 D). HDAC1 overexpression did not aff  ect 
glucocorticoid sensitivity (Fig. 5 D, bottom). Furthermore, 
40% KD of HDAC 2 in sputum macrophages from healthy 
nonsmokers by RNAi caused a reduction in the inhibitory 
eff  ect of Dex (10−8 M) from 62 to 36% (Fig. 5 E).
Collectively, our results show that HDAC2 is a key pro-
tein involved in the suppression of p65–NF-κB–mediated 
  infl  ammatory gene expression, which occurs at low concen-
trations of Dex, whereas modulation of HDAC2 expression 
does not reduce GR-mediated gene induction. HDAC2 acts 
by deacetylating GR, thereby enabling p65–NF-κB associa-
tion and subsequent attenuation of proinfl  ammatory  gene 
transcription. The importance of this mechanism in COPD, 
a glucocorticoid-insensitive disease, is emphasized by over-
expression of HDAC2, which restores glucocorticoid sensi-
tivity in primary cells from these patients.
MATERIALS AND METHODS
Cultured cells and alveolar macrophages.  The human lung adenocar-
cinoma type II cell line (A549 cells) was purchased from American Type 
  Culture Collection. Healthy nonsmokers, current healthy smokers, and 
  patients with stage 2–3 COPD were recruited. The study was approved 
by the Brompton Harefi  eld and National Heart and Lung Institute Ethics 
Figure 5.  Overexpression of HDAC2 restores glucocorticoid 
  sensitivity in alveolar macrophages from COPD patients. (A) Total 
HDAC activity (closed bar) and immunoprecipitated HDAC2 (shaded 
bar) activity in nuclear extracts. * and **, P < 0.05 and P < 0.001, 
  respectively versus healthy nonsmokers; #, P < 0.05 versus smokers. 
(B) Representative image of HDAC2 protein expression in nuclear ex-
tracts 24 h after transfection with vehicle (NT), empty vector (Em), and 
HDAC2 vector (H2). (C) Acetylation level of immunoprecipitated GR of 
alveolar macrophages from normal (N), smoker (S), and COPD patients 
(C). Cells were stimulated with 10−8 M Dex for 1 h. (D) 100 ng/ml 
LPS-induced GM-CSF production in the absence (closed bar) or pres-
ence (shaded bar) of 10−8 M Dex (for 20 min) 24 h after transfection 
with each vector. Open bars are unstimulated control samples. 
*, P < 0.05 versus LPS control (n = 6 experiments). (E) LPS-induced 
GM-CSF production in nontreated (NT), Sc, or HDAC2 siRNA 
(H2)–transfected   sputum macrophages in the absence (closed bar) 
or presence (shaded bar) of 10−8 M Dex for 20 min. *, P < 0.05. Values 
in A, D, and E represent means ± SEM.12  HDAC2-DEPENDENT GR DEACETYLATION ON NF-κB SUPPRESSION | Ito et al.
Committees, and all subjects gave signed informed consent. Bronchoscopy, 
bronchoalveolar lavage, isolation of bronchoalveolar lavage, and sputum 
macrophages were performed as previously described (24, 25).
RNA interference. 100-nM siRNA sequences were transfected using 
Gene Silencer (GTS Inc.) for A549 cells and jetSI (Polyplus-transfection SA) 
for sputum macrophages. siRNAs were prepared with a GeneSilencer kit 
(Ambion) or purchased from QIAGEN or Dharmacon. Duplexes used were 
HDAC1 (SMART pool [Dharmacon] and nt 89), HDAC2 (nt 96, 177, 642, 
and 813), HDAC3 (SMART pool [Dharmacon] and nt 411), and HDAC8 
(nt 155 and 373). Nonspecifi  c control duplex (Sc, 47% guanine-cytosine 
content) was also purchased from Dharmacon.
Overexpression of HDAC.  Plasmids (pcDNA3.1) containing the HDAC1 
and HDAC2 genes were donated by S. Georas (Johns Hopkins University, 
Baltimore, MD). Alveolar macrophages (3 × 105 cells/well) were transfected 
using jetPEI-Man (Polyplus-transfection SA).
Quantitative RT-PCR. Total RNA extraction and reverse transcription 
were performed using an RNeasy kit (QIAGEN) and an Omniscript RT kit 
(QIAGEN). Gene transcript level of SLPI and GAPDH were quantifi  ed by 
real-time PCR using a QuantiTect SYBR Green PCR kit (QIAGEN) on a 
Rotor-Gene 3000 (Corbett Research).
Cytokine ELISAs.  IL-8 and GM-CSF concentrations were determined by 
sandwich ELISA (R&D Systems) and normalized to cell number as deter-
mined by MTT assay.
GRE binding assay.  Biotinated oligonucleotide duplexes containing two 
GREs (26) were incubated in streptavidin-conjugated 96-well plates 
(Thermo Labsystems). GR binding to oligonucleotides were colormetrically 
detected in nuclear extracts (19) by an enzyme-immunosorbent method   using 
an anti-GR antibody (Santa Cruz Biotechnology, Inc.).
Western blotting and dot blotting. Nuclear extracts and immunopre-
cipitated samples were prepared and evaluated by conventional SDS-PAGE/
Western blotting (19). Determination of HDAC protein expression after 
RNAi was performed by dot blot analysis.
Immuno- or oligonucleotide precipitation of GR.  GR was immuno-
precipitated in whole cell extracts with anti-GR antibody–conjugated A/G 
agarose beads. GR was also precipitated with avidin-agarose beads conjugated 
with biotinylated oligonucleotides containing 2 × GRE (5′-aagattcaggtcatg-
acctgaggaga-3′) or coimmunoprecipitated with p65–NF-κB antibody–
  conjugated A/G agarose beads in nuclear extracts in the presence of 10−8 M 
Dex and 1 ng/ml IL-1β.
ChIP assay. ChIP with panacetylated histone 4 antibody (ChIP assay kit; 
Upstate Biotechnology) was performed at the GM-CSF promoter region as 
previously described (19) using the aforementioned real-time PCR system.
Site-directed mutagenesis.  Site-directed mutagenesis was performed us-
ing Gene Tailor Site-Directed Mutagenesis system (Invitrogen).
HDAC activity. HDAC activity was measured with HDAC Fluorescent 
Activity Assay kit (BIOMOL Research Laboratories, Inc.).
NF-𝗋B activation. NF-κB activation was determined with NF-κB TransAM 
kit (Active Motif).
Luciferase assays.  Plasmids containing two GRE-luciferases were donated 
by J. Bloom (University of Arizona, Tucson, AZ). Plasmids were transfected 
to A549 cells with pSV–β-galactosidase (Promega) using Lipofectamine 2000 
(Invitrogen) as described previously (27).
Statistics.  Results are expressed as means ± SEM. Analysis of variance was 
performed by Kruskal-Wallis analysis and, when signifi  cant comparisons 
were made, by Mann-Whitney U test using the analysis package SPSS 10.0 
(SPSS Inc.). P < 0.05 was considered statistically signifi  cant.
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